Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL
Ibrutinib, a Bruton tyrosine kinase inhibitor, provides effective treatment for chronic lymphocytic leukemia (CLL). Here, the authors describe time-dependent molecular changes to malignant cells and to the immune system in patients undergoing ibrutinib therapy, with can be used for therapy monitorin...
Guardado en:
Autores principales: | André F. Rendeiro, Thomas Krausgruber, Nikolaus Fortelny, Fangwen Zhao, Thomas Penz, Matthias Farlik, Linda C. Schuster, Amelie Nemc, Szabolcs Tasnády, Marienn Réti, Zoltán Mátrai, Donát Alpár, Csaba Bödör, Christian Schmidl, Christoph Bock |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/73b869eadff94edea5bfbf6a4cfbce75 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
por: Ujjani C, et al.
Publicado: (2020) -
Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
por: Joanne E. Davis, et al.
Publicado: (2021) -
Single-Cell Sequencing: Biological Insight and Potential Clinical Implications in Pediatric Leukemia
por: Donát Alpár, et al.
Publicado: (2021) -
Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks
por: André F. Rendeiro, et al.
Publicado: (2016) -
Biology and Treatment of High-Risk CLL: Significance of Complex Karyotype
por: Thomas Chatzikonstantinou, et al.
Publicado: (2021)